{"classes":[{"categories":[{"measurements":[{"comment":"Kaplan-Meier median estimate not reached.","groupId":"OG000","lowerLimit":"4.1","upperLimit":"NA","value":"NA"},{"comment":"Kaplan-Meier median estimate not reached.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with hodgkin lymphoma.","id":"OG000","title":"Cohort 2"},{"description":"Participants with non-hodgkin's lymphoma","id":"OG001","title":"Cohort 4"}],"paramType":"MEDIAN","populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)","title":"DOR as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma","type":"SECONDARY","unitOfMeasure":"Months"}